Epilepsy Research
Volume 83, Issue 1 , Pages 1-43 , January 2009

Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX)

  • Meir Bialer

      Affiliations

    • Department of Pharmaceutics, School of Pharmacy and David R. Bloom Centre for Pharmacy, Faculty of Medicine, Ein Karem, The Hebrew University of Jerusalem, 91120 Jerusalem, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 2 6758610; fax: +972 2 6757246.
    • ,
  • Svein I. Johannessen

      Affiliations

    • The National Center for Epilepsy, Sandvika, Division of Clinical Neuroscience, Rikshospitalet University Hospital, Oslo, Norway
    • ,
  • René H. Levy

      Affiliations

    • Department of Pharmaceutics and Neurological Surgery, University of Washington, Seattle, WA, USA
    • ,
  • Emilio Perucca

      Affiliations

    • Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, and Institute of Neurology IRCCS C. Mondino Foundation, Pavia, Italy
    • ,
  • Torbjörn Tomson

      Affiliations

    • Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
    • ,
  • H. Steve White

      Affiliations

    • Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA

Received 15 July 2008 ,Revised 7 September 2008 ,Accepted 15 September 2008.

References 

  1. Adkins EM, Smith MD, Pruess T, Grussendorf E, Green B, Bulaj G, et al. NAX-5055: a metabolically stable galanin-based neuropeptide with potent anticonvulsant and antinociceptive actions. Epilepsia. 2007;48(Suppl. 6):292
  2. Alles GA, Ellis CH, Feigen GA, Redemann MA. Comparative central depressant actions of some 5-phenyl-5-alkyl barbituric acids. J. Pharmacol. Exp. Ther. 1947;89:356–367
  3. Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics. 2007;4:88–96
  4. Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur. J. Clin. Pharmacol. 2008;64:267–273
  5. Almeida, L., Bialer, M., Soares-da-Silva, P., in press. Eslicarbazepine acetate. In: Shorvon, S., Perucca, E., Engel, J. (Eds.), Treatment of Epilepsy, 3rd ed., Wiley-Blackwell, Oxford, UK.
  6. Amann B, Sterr A, Vieta E, Stampfer R, Walden J, Grunze H. An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients. J. Clin. Psychopharmacol. 2006;26:534–536
  7. Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn-Schmiedeberg's Arch. Pharmacol. 1999;359:33–39
  8. Barton ME, Klein BD, Wolf HH, White SH. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001;47:217–227
  9. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48:1308–1317
  10. Berwick J, Johnston D, Jones M, Martindale J, Martin C, Kennerly AJ, et al. Fine detail of neurovascular coupling revealed by spatio-temporal analysis of the hemodynamic response to single whisker stimulation in rat barrel cortex. J. Neurophysiol. 2008;99:787–798
  11. Biagini G, Baldelli E, Longo D, Pradelli L, Zini I, Rogawski MA, et al. Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy. Exp. Neurol. 2006;201:519–524
  12. Biagini, G., Longo, D., Baldelli, E., Zoli, M., Rogawski, M.A., Bertazzoni G., Avoli, M., in press. Neurosteroids and epileptogenesis in the pilocarpine model: evidence for a relationship between P450scc induction and length of the latent period. Epilepsia.
  13. Bialer M. Clinical pharmacology of valpromide. Clin. Pharmacokinet. 1991;20:114–122
  14. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin. Investig. Drugs. 2006;15:637–647
  15. Bialer M, Yagen B. Valproic acid—second generation. Neurotherapeutics. 2007;4:130–137
  16. Bialer M, Johannessen S, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 2002;51:31–71
  17. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. 2004;34:1–41
  18. Bialer M, Johannessen S, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res. 2007;73:1–52
  19. Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur. J. Pharmacol. 2003;460:109–116
  20. Brandt C, Heile A, Potschka H, Stoehr T, Loscher W. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia. 2006;47:1803–1809
  21. Brodsky A, Costantini C, von Rosenstiel P. Safety and tolerability of brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia. 2007;48(Suppl. 6):342
  22. Bulaj, G., Green, B.R., Lee H-K., Roberston, C.R., White, K., Zhang, L., Sochanska, M., Flynn, S.P., Scholl, E.A., Pruess, T.H., Smith, M.D., White, H.S. Design, synthesis and characterization of high-affinity, systemically-active galanin analogs with potent anticonvulsant activities. J. Med. Chem., 2008, in press.
  23. Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3(-hydroxy-3(-methyl-5(-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acidA receptor. J. Pharmacol. Exp. Ther. 1997;280:1284–1295
  24. Cawello W, Kropeit D, SchiltmeyerB , Hammes W, Horstmann R. Food does not affect the pharmacokinetics of SPM 927. Epilepsia. 2004;45(Suppl. 7):307;(Abstract 2.342)
  25. Chan WN, Evans JM, Hadley MS, Herdon HJ, Jerman JC, Parsons AA, et al. Identification of (−)-cis-6-acetyl-4S-(3-choro-4-Fluoro-benzoylamino)-3,4-dihydro-2,2-dimethyl-2H-benzo-[b]pyran-3S-ol as a potential antimigraine agent. Bioorg. Med. Chem. Lett. 1999;2:285–290
  26. Chien S, Bialer M, Solanki B, Verhaeghe T, Doose DR, Novak G, et al. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. Epilepsia. 2006;47:1830–1840
  27. Chien S, Yao C, Mertens A, Verhaeghe T, Solanki B, Doose DR, et al. An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid. Epilepsia. 2007;48:1328–1338
  28. Chung S, Sperling M, Biton V, Krauss G, Doty P, Sullivan T the SP754 Study Group. Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48(Suppl. 7):57
  29. Czech T, Yang JW, Csaszar E, Kappler J, Baumgartner C, Lubec G. Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem. Res. 2004;29:2189–2196
  30. Dost R, Rundfeldt C. The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca++ and low Mg++ model in the hippocampal slice preparation. Epilepsy Res. 2000;38:53–66
  31. Dost R, Rostock A, Rundfeldt C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004;369:382–390
  32. Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics. 2007;4:145–148
  33. Dretchen KL, Bowles AM, Raines A. Protection by phenytoin and calcium channel blocking agents against the toxicity of diisopropylfluorophosphate. Toxicol. Appl. Pharmacol. 1986;83:584–589
  34. Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-Silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia. 2007;48:497–504
  35. Errington AC, Coyne L, Stöhr T, Selve N, Lees G. Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology. 2006;50:1016–1029
  36. Foreman M, Hanania T, Stratton S, Wilcox K, White HS, Stables J, et al. In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. Pharmacol. Biochem. Behav. 2008;89:523–534
  37. Francois J, Ferrandon A, Koning E, Nehlig A. A new drug, RWJ-33369, protects limbic areas in the lithium-pilcarpine model (lipilo) of epilepsy and delays or prevents the occurrence of spontaneous seizures. Epilepsia. 2005;46:269–270(abstract)
  38. Francois J, Boehrer A, Nehlig A. Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS. Epilepsia. 2008;49:393–399
  39. French JA, Brodsky A, von Rosenstiel P on behalf of the Brivaracetam N01193 Study Group. Efficacy and tolerability of 5, 20 and 50mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset seizures. Epilepsia. 2007;48(Suppl. 6):400
  40. Funk AP, Ricci R, Anderson BA, Arana AB, De Colle C, Wang S, et al. Single doses of JZP-4 decrease cortical excitability. A transcranial magnetic stimulation study. In: American Epilepsy Society 2008 Annual Meeting. 2008;
  41. Ganes, D., Moros, D., Levitt, B., Rutman, H., LeBel, M., Yacobi, A., 2006. Safety and pharmacokinetics of T2000, a novel non-sedating barbiturate, after multiple oral doses in healthy subjects. American Association of Pharmaceutical Scientists Annual Meeting and Exposition, October 29–November 2, San Antonio, TX (www.aapsj.org/abstracts/AM_2006/AAPS2006-003327.pdf).
  42. Garriga-Canut M, Schoenike B, Qazi R, Bergendahl K, Daley TJ, Pfender R, et al. 2-Deoxy-d-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat. Neurosci. 2006;9:1382–1387
  43. Grabenstatter H, Dudek F. The use of chronic models in antiepileptic drug discovery: the effect of RJW-333369 on spontaneous motor seizures in rats with kainite-induced epilepsy. Epilepsia. 2004;45:197;(abstract)
  44. Grabenstatter, H.L., Dudek, F.E., 2008. A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia, 2008 May 20 [Epub ahead of print].
  45. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Suillvan T. Lacosamide: efficacy and safety as oral adjunctive therapy in adults with partial seizures. Epilepsia. 2006;47(Suppl. 4):3;(abstract)
  46. Hansen IL, Levy MM, Kerr DS. The 2-deoxyglucose test as a supplement to fasting for detection of childhood hypoglycemia. Ped. Res. 1984;18:359–364
  47. He XP, Kotloski R, Nef S, Luikart B, Parada LF, McNamara JO. Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model. Neuron. 2004;43:31–42
  48. Herd MB, Belelli D, Lambert JJ. Neurosteroid modulation of synaptic and extrasynaptic GABAA receptors. Pharmacol. Ther. 2007;116:20–34
  49. Herdon HJ, Jerman JC, Stean TO, Middlemiss DN, Chan WN, Vong AK, et al. Characterization of the binding of [3H]-SB-204269, a radiolabelled form of the new anticonvulsant SB-204269, to a novel binding site in rat brain membranes. Br. J. Pharmacol. 1997;121:1687–1691
  50. Hetka R, Rundfeldt C, Heinemann U, Schmitz D. Retigabine strongly reduces repetitive firing in rat entorhinal cortex. Eur. J. Pharmacol. 1999;386:165–171
  51. Hirano K, Kuratani K, Fujiyoshi M, Tashiro N, Hayashi E, Kinoshita M. Kv7.2-7.5 voltage-gated potassium channel (KCNQ2-5) opener, retigabine, reduces capsaicin-induced visceral pain in mice. Neurosci. Lett. 2007;413:159–162
  52. Horstmann R, Bonn R, Cawello W, Doty P, Rudd D. Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927. Epilepsia. 2002;43(Suppl. 7):188;(Abstract 2.174)
  53. Hosie AD, Wilkins ME, da Silva HMA, Smart TG. Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature. 2006;444:486–489
  54. Hovinga CA. SPM-927 (schwarz pharma). Drugs. 2003;6:479–485
  55. Huguenard JR, Wilson WA. Suppression of repetitive firing of neurons by diphenylbarbituric acid. J. Pharmacol. Exp. Ther. 1985;232:228–231
  56. Isoherranen N, Woodhead JH, White HS, Bialer M. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia. 2001;42:831–836
  57. Isoherranen N, Yagen B, Woodhead JH, Spiegelstein O, Blotnik S, Wilcox KS, et al. Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. Br. J. Pharmacol. 2003;138:602–613
  58. Kaminski RM, Gasior M, Carter RB, Wilkin JM. Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice. Eur. J. Pharmacol. 2003;474:217–222
  59. Kaminski RM, Livingood MR, Rogawski MA. Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia. 2004;45:864–867
  60. Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology. 2008;54:715–720
  61. Kasteleijn-Nolst Trenité DG, Genton P, Parain D, Masnou P, Steinhoff BJ, Jacobs T, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology. 2007;69:1027–1034
  62. Kasteleijn-Nolst Trenité DGA, Biton V, Wang S, De Colle C, Isojarvi J. Evidence of activity for JZP-4, a novel sodium and calcium channel inhibitor in photosensitive epilepsy patients, an exploratory study. In: American Epilepsy Society 2008 Annual Meeting. 2008;
  63. Kaufmann D, Yagen B, Minert A, Tal M, Devor M, Bialer M. Evaluation of the enantioselective antiallodynic profile and pharmacokinetics of propylisopropylacetamide, a chiral isomer of valproic acid amide. Neuropharmacology. 2008;54:699–707
  64. Kerrigan JF, Shields WD, Nelson TY, Bluestone DL, Dodson WE, Bourgeois BF, et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res. 2000;42:133–139
  65. Kinney GA, Emmerson PJ, Miller RJ. Galanin receptor-mediated inhibition of glutamate release in the arcuate nucleus of the hypothalamus. J. Neurosci. 1998;18:3489–3500
  66. Klein B, Smith MD, White HS. The novel neuromodulator carisbamate delays the acquisition of rat amygdala kindling and maintains acute antiepileptic activity when evaluated in post-kindled rats. In: Presented at: the 61st Annual Meeting of the American Epilepsy Society. Philadelphia, PA, USA, November 30–December 4. 2007;
  67. Matagne A, Klitgaard H. Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man. Epilepsy Res. 1998;31:59–71
  68. Knoefel PK, Lehmann G. The anticonvulsant action of diphenylhydantoin and some related compounds. J. Pharmacol. Exp. Ther. 1942;76:194–201
  69. Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strøbaek D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J. Pharmacol. Exp. Ther. 2005;314:282–292
  70. Kropeit D, Schiltmeyer B, Cawello W, Hammes W, Horstmann R. Bioequivalence of short-time infusions compared to oral administration of SPM 927. Epilepsia. 2004;45(Suppl. 7):123;(Abstract 1.323)
  71. Lacroix B, von Rosenstiel P, Sargentini-Maier ML. Population pharmacokinetics of brivaracetam in patients with partial epilepsy. Epilepsia. 2007;48(Suppl. 6):333
  72. Laveille C, Lacroix B, Snoeck E, Sargentini-Maier ML, von Rosenstiel P, Stockis A. Dose- and exposure-response modeling of brivaracetam add-on treatment in patients with partial epilepsy. Epilepsia. 2007;48(Suppl. 6):328
  73. Lawrence JJ, Goldschen M, Jones M, Rogawski MA, McBain CJ. The Kv7/KCNQ/M channel opener ICA-027243 arrests interneuronal firing and reduces interneuronal network synchrony in the hippocampus: novel insights into the antiepileptic action of Kv7 channel openers. Epilepsia. 2007;48(Suppl. 6):361;(Abstract 3.307)
  74. Laxer K, Blum D, Abou-Khalil BW, Morrell MJ, Lee DA, Data JL, et al. Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Epilepsia. 2000;41:1187–1194
  75. Leśkiewicz M, Budziszewska B, Jaworska-Feil L, Kubera M, Basta-Kaim , Lason W. Inhibitory effect of some neuroactive steroids on cocaine-induced kindling in mice. Polish J. Pharmacol. 2003;55:1131–1136
  76. Lian XY, Khan FA, Stringer JL. Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats. J. Neurosci. 2007;27:12007–12011
  77. Maia J, Almeida L, Falcão A, Soares E, Mota F, Potgieter JH, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int. J. Clin. Pharmacol. Ther. 2008;46:119–130
  78. Main MJ, Cryan JE, Dupere JRB, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol. 2000;58:253–262
  79. Mannens GS, Hendrickx J, Janssen CG, Chien S, Van HB, Verhaeghe T, et al. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-,2-carbamate, [S]-) in humans. Drug Metab. Dispos. 2007;35:554–565
  80. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for treatment of generalized and unclassifiable epilepsy: an unblinded randomized controlled trial. Lancet. 2007;369:1016–1026
  81. Matagne A, Margineanu D-G, Kenda B, Michel P, Klitgaard H. Anticonvulsive and antiepileptic properties of brivaracetam (ucb 34714), a high affinity synaptic vesicle protein SV2A ligand. Br. J. Pharmacol. 2008;154:1662–1671
  82. Mazarati A, Lu X. Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors. Neuropeptides. 2005;39:277–280
  83. Mazarati AM, Halászi E, Telegdy G. Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats. Brain Res. 1992;589:164–166
  84. Mazarati AM, Liu H, Soomets U, Sankar R, Shin D, Katsumori H, et al. Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J. Neurosci. 1998;18:10070–10077
  85. Mazarati A, Langel U, Bartfai T. Galanin: an endogenous anticonvulsant?. Neuroscientist. 2001;7:506–517
  86. Mazarati A, Lundström L, Sollenberg U, Shin D, Langel U, Sankar R. Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: the effects of subtype-selective agonists and the role of G-protein-mediated signalling. J. Pharmacol. Exp. Ther. 2006;318:700–708
  87. McElvain SM. 5,5-Diphenylbarbituric acid. J. Am. Chem. Soc. 1935;57:1303–1304
  88. McKay, G., Hawes, E.M., Hogge, L., Peng, P., Ganes, D., Yacobi, A., 2006a. Identification of the metabolites of T2000, a novel non-sedating barbiturate, in human. American Association of Pharmaceutical Scientists Annual Meeting and Exposition, October 29–November 2, San Antonio, TX (www.aapsj.org/abstracts/AM_2006/AAPS2006-001703.pdf).
  89. McKay, G., Hawes, E.M., Hogge, L., Peng, P., Ganes, D., Yacobi, A., 2006b. Metabolism of T2000, a novel non-sedating barbiturate, in rat and dog. American Association of Pharmaceutical Scientists Annual Meeting and Exposition, October 29–November 2, San Antonio, TX (www.aapsj.org/abstracts/AM_2006/AAPS2006-003495.pdf).
  90. Melmed C, Moros D, Rutman H. Treatment of essential tremor with the barbiturate T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid). Movement Disord. 2007;22:723–727
  91. Merritt HH, Putnam TJ. A new series of anticonvulsant drugs tested by experiments on animals. Arch. Neurol. Psychiatry. 1938;39:1003–1015
  92. Merritt HH, Putnam TJ. Experimental determination of anticonvulsive activity of chemical compounds. Epilepsia. 1945;3:51–75
  93. Monaghan EP, Navalta LA, Shum L, Ashbrook DW, Lee DA. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia. 1997;38:1026–1031
  94. Moore KT, Zannikos P, Solanki B, Greenspan A, Romano G, Brashear HR. Single-dose pharmacokinetics of carisbamate in subjects with normal and impaired hepatic function. Clin. Pharmacol. Ther. 2008;83(Suppl. 1):S24
  95. Moros D, Rutman H. T2000 A non-sedating barbiturate with antiepileptic activity under study in essential tremor. In: Antiepileptic Drug Trials IX Syllabus. Sunny Isles Beach, FL, USA, March 21–24. 2007;
  96. Munro G, Erichsen HK, Mirza NR. Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology. 2007;53:609–618
  97. Newman G, Hospod F, Patlak C. Kinetic model of 2-deoxyglucose metabolism using brain slices. J. Cereb. Blood. Flow Metab. 1990;10:510–526
  98. Nguyen, L., Tao, L., Nash, J., Peng, P., Ganes, D., Yacobi, A., 2006. Evaluation of the potential for drug–drug interactions of T2000 and its major metabolites in human liver microsomes and primary human hepatocytes in culture. American Association of Pharmaceutical Scientists Annual Meeting and Exposition, October 29–November 2, San Antonio, TX (www.aapsj.org/abstracts/AM_2006/AAPS2006-002694.pdf).
  99. Nguyen, L., Gagnon, S., Erlemann, K.-R., Tao, L., Nash, J., Peng, P., Ganes, D., Yacobi, A., 2007. Induction of cytochromes P450 in Sprague–Dawley rats and Beagle dogs following dosing with T2000 and comparison to the inductive response in primary human hepatocytes. American Association of Pharmaceutical Scientists Annual Meeting and Exposition, November 11–15, 2007, San Diego, CA (www.aapsj.org/abstracts/AM_2007/AAPS2007-001507.pdf).
  100. Nielsen AN, Mathiesen C, Blackburn-Munro G. Pharmacological characterisation of acid-induced muscle allodynia in rats. Eur. J. Pharmacol. 2004;487:93–103
  101. Nohria V, Giller E. Ganaxolone. Neurotherapeutics. 2007;4:102–105
  102. Otoul C, von Rosenstiel P, Stockis A. Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial-onset seizures. Epilepsia. 2007;48(Suppl. 6):334
  103. Otto JF, Kimball MM, Wilcox KS. Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. Mol. Pharmacol. 2002;61:921–927
  104. Parada A, Soares-da-Silva P. The novel anticonvu comparison with carbamazepine and oxcarbazepine. Neurochem. Int. 2002;40:435–440Parada A, Soares-da-Silva P. Lsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Nurochem. Int. 2002;40:435–440
  105. Parsons AA, Bingham S, Raval P, Read S, Thompson M, Upton N. Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br. J. Pharmacol. 2001;132:1549–1557
  106. Pieribone VA, Tsai J, Soufflet C, Rey E, Shaw K, Giller E, et al. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy. Epilepsia. 2007;48:1870–1874
  107. Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology. 2007;68:1197–1204
  108. Raez LE, Langmuir V, Tolba K, Rocha-Lima CM, Papadopoulos K, Kroll S, et al. Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas. ASCO Annual Meeting Proceedings. J. Clin. Onc. 2007;25(18S):14025
  109. Raines A, Niner JM, Pace DG. A comparison of the anticonvulsant, neurotoxic and lethal effects of diphenylbarbituric acid, phenobarbital and diphenylhydantoin in the mouse. J. Pharmacol. Exp. Ther. 1973;186:315–322
  110. Raines A, Baumel I, Gallagher BB, Niner JM. The effects of 5,5-diphenylbarbituric acid on experimental seizures in rats: correlation between plasma and brain concentrations and anticonvulsant activity. Epilepsia. 1975;16:575–581
  111. Raines A, Ganes D, Levitt B, Moros D, LeBel M, Rutman H, et al. Enhancement by a high fat meal of the absorption of orally administered T2000 (1,3-bismethoxymethyl-5,5-diphenylbarbituric acid; I) in man. Experimental Biology. Washington, DC, April 28–May 2, FASEB J. 2007;21:566.2
  112. Read SJ, Smith MI, Hunter AJ, Upton AJ, Parsons AA. SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetised cat. Cephalalgia. 2000;20:92–99
  113. Read SJ, Hirst WD, Upton N, Parsons AA. Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan. Brain Res. 2001;891:69–77
  114. Reddy DS, Rogawski MA. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J. Pharmacol. Exp. Ther. 2000;295:1241–1248
  115. Richter A, Tober C, Rundfeldt C. Antidystonic effects of Kv7 (KCNQ) channel openers in the dt sz mutant, an animal model of primary paroxysmal dystonia. Br. J. Pharmacol. 2006;149:747–753
  116. Rogawski MA, Reddy DS. Neurosteroids: endogenous modulators of seizure susceptibility. In:  Rho JM,  Sankar R,  Cavazos J editor. Epilepsy: Scientific Foundations of Clinical Practice. New York: Marcel Dekker; 2004;p. 319–355
  117. Rolan P, Sargentini-Maier ML, Pigeolet E, Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males. Br. J. Clin. Pharmacol. 2008;66:71–75
  118. Rosillon D, Astruc B, Hulhoven R, Meeus MA, Troenaru MM, Watanabe S, et al. Effect of brivaracetam on cardiac repolarisation—a thorough QT study. Curr. Med. Res. Opin. 2008;24:2327–2337
  119. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos E, et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 1996;23:211–223
  120. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transected with human KDNQ2/3 subunits. Neurosci. Lett. 2000;281:73–76
  121. Sander SE, Richter A. Antidyskinetic effects of the KV7 channel opener retigabine in an animal model of levodopa-induced dyskinesia.. In: Göttingen Meeting of the German Neuroscience Society Göttingen. Germany. 2007;T35-4A
  122. Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br. J. Clin. Pharmacol. 2007;63:680–688
  123. Sargentini-Maier ML, Espié P, Coquette A, Stockis A. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab. Dispos. 2008;36:36–45
  124. Schachter, S., White H.S., Murphree L., Stables, J., 2006. Anticonvulsant activity of Huperzine A, an alkaloid extract of Chinese club moss (Huperzia serrata), in the 6-Hz model of psychomotor seizures. http://www.aesnet.org/go/publications/aes-abstracts/abstractsearch/?mode=display&st=Schachter&sy=2006&sb=All&startrow=1&id=6996. Abstract 4.087.
  125. Schiltmeyer B, Cawello W, Kropeit D, Hammes W, Horstmann R. Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender. Epilepsia. 2004;45(Suppl. 7):313;(Abstract 2.361)
  126. Shimshoni J, Dalton EC, Jenkins E, Eyal S, Ewen K, Williams RSB, et al. The effect of CNS-active valproic acid constitutional isomers, cyclopropyl analogues and amide derivatives on neuronal growth cone behavior. Mol. Pharmacol. 2007;71:884–892
  127. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 1977;28:897–916
  128. Spiegelstein O, Yagen B, Levy RH, Finnell RH, Bennett GD, Roeder M, et al. Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid. Pharm. Res. 1999;16:1582–1588
  129. Srivastava AK, White HS. Retigabine decreases behavioral and electrographic seizures in the lamotrigine-resistant amygdal kindled rat model of pharmacoresistant epilepsy. Epilepsia. 2005;46(Suppl. 8):217;(Abstract 2.375)
  130. Stafstrom, C.E., Ockuly, J.C, Murphree, L., Valley, M.T., Roopra, A., Sutula, T.P. Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models. Submitted for publication.
  131. Stoehr T, Kupferberg HJ, Stables JP, Choi D, Harris RH, Kohn H, et al. Lacosamide, a novel anticonvulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 2007;74:147–154
  132. Tatulian L, Brown DA. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J. Physiol. 2003;549:57–63
  133. Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J. Neurosci. 2001;21:5535–5545
  134. Thomas D, Scharfenecker U, Schiltmeyer B, et al. Low potential for drug–drug interaction of lacosamide. Epilepsia. 2006;47(Suppl. 4):200;(abstract)
  135. Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129 a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol. 1996;303:163–169
  136. Thomas D, Scharfenecker U, Schiltmeyer B, Cawello W, Doty P, Horstmann R. Low potential for drug–drug interaction of lacosamide. Epilepsia. 2006;47(Suppl. 4):200;(abstract)
  137. Tremblay, P., Shink, E., Abolfathi, Z., Tanguay, M., Lebel, M., Peng, P., Ganes, D., Yacobi, A., 2006. Pharmacokinetic modeling of the novel non-sedating barbiturate T2000 and its active metabolites in plasma and urine. American Association of Pharmaceutical Scientists Annual Meeting and Exposition, October 29–November 2, San Antonio, TX (www.aapsj.org/abstracts/AM_2006/AAPS2006-003092.pdf).
  138. Upton N, Raval P, Herdon H, Jerman J, Parsons AA. SB-220453, a mechanistically novel benzopyran compound, inhibits trigeminal nerve ganglion (TGN) stimulation-induced carotid vasodilation. Cephalalgia. 1999;19:351
  139. van Paesschen W, Brodsky A on behalf of the Brivaracetam N01114 Study Group. Efficacy and tolerability of 50 and 150mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial-onset epilepsy. Epilepsia. 2007;48(Suppl. 6):329
  140. Ward J, Caprio V. A radical mediated approach to the core structure of Huperzine A. Tetrahedron Lett. 2006;47:553–556
  141. Wasterlain C, Suchomelova L, Matagne A, Klitgaard H, Mazarati A, Shinmei S, et al. Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia. 2005;46(Suppl. 8):219
  142. White HS, Schachter S, Lee D, Xiaoshen J, Eisenberg D. Anticonvulsant activity of Huperzine A, an alkaloid extract of Chinese club moss (Huperzia serrata). Epilepsia. 2005;46(Suppl. 8):220
  143. White H, Srivastava A, Klein B, et al. The novel investigational neuromodulator RWJ-333369 displays a broad-spectrum anticonvulsant profile in rodent seizure and epilepsy models (abstract). Epilepsia. 2006;27:200
  144. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol. Pharmacol. 2005;67:1009–1017
  145. Xu T, Bajjalieh SM. SV2 modulates the size of the readily releasable pool of secretary vesicles. Nat. Cell Biol. 2001;3:691–698
  146. Yacobi, A., Ganes, D., Callozzo, J., Lai, C., Peng, P, 2006. Examination of in vitro protein binding of T2000, a novel non-sedating barbiturate, in mouse, rat, rabbit, dog and human plasma. American Association of Pharmaceutical Scientists Annual Meeting and Exposition, October 29–November 2, San Antonio, TX (www.aapsj.org/abstracts/AM_2006/AAPS2006-003222.pdf).
  147. Yao C, Doose DR, Novak G, Bialer M. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Epilepsia. 2006;47:1822–1829
  148. Zangara A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol. Biochem. Behav. 2003;75:675–686
  149. Zavadil AP, Dretchen KL, Raines A. Diphenylbarbituric acid: its effects on neuromuscular and spinal cord function in the cat. Epilepsia. 1985;26:158–166

PII: S0920-1211(08)00261-1

doi: 10.1016/j.eplepsyres.2008.09.005

Epilepsy Research
Volume 83, Issue 1 , Pages 1-43 , January 2009

Article Tools

* Image Usage & Resolution